Diffusion-Weighted Magnetic Resonance Imaging Early After Chemoradiotherapy to Monitor Treatment Response in Head-and-Neck Squamous Cell Carcinoma
Creators
- 1. Department of Radiology, University Hospitals Leuven (Belgium)
- 2. Department of Radiation Oncology, Leuven Cancer Institute, University Hospitals Leuven (Belgium)
- 3. Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven (Belgium)
- 4. Department of Pathology, University Hospitals Leuven (Belgium)
Description
Purpose: To evaluate diffusion-weighted imaging (DWI) for assessment of treatment response in head and neck squamous cell carcinoma (HNSCC) three weeks after the end of chemoradiotherapy (CRT). Methods and Materials: Twenty-nine patients with HNSCC underwent magnetic resonance imaging (MRI) prior to and 3 weeks after CRT, including T2-weighted and pre- and postcontrast T1-weighted sequences and an echo-planar DWI sequence with six b values (0 to 1,000 s/mm2), from which the apparent diffusion coefficient (ADC) was calculated. ADC changes 3 weeks posttreatment compared to baseline (∆ADC) between responding and nonresponding primary lesions and adenopathies were correlated with 2 years locoregional control and compared with a Mann-Whitney test. In a blinded manner, the ∆ADC was compared to conventional MRI 3 weeks post-CRT and the routinely implemented CT, on average 3 months post-CRT, which used size-related and morphological criteria. Positive and negative predictive values (PPV and NPV, respectively) were compared between the ∆ADC and anatomical imaging. Results: The ∆ADC of lesions with later tumor recurrence was significantly lower than lesions with complete remission for both primary lesions (−2.3% ± 0.3% vs. 80% ± 41%; p < 0.0001) and adenopathies (19.9% ± 32% vs. 63% ± 36%; p = 0.003). The ∆ADC showed a PPV of 89% and an NPV of 100% for primary lesions and a PPV of 70% and an NPV of 96% for adenopathies per neck side. DWI improved PPV and NPV compared to anatomical imaging. Conclusion: DWI with the ∆ADC 3 weeks after concluding CRT for HNSCC allows for early assessment of treatment response.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.ijrobp.2011.02.044Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2011.02.044;
- PII
- S0360-3016(11)00364-6;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 82
- Journal Issue
- 3
- Journal Page Range
- p. 1098-1107
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 44016474
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- CARCINOMAS; COMBINED THERAPY; DIFFUSION; HEAD; NECK; NMR IMAGING; PATIENTS
- Descriptors DEC
- BODY; DIAGNOSTIC TECHNIQUES; DISEASES; MEDICINE; NEOPLASMS; THERAPY
Optional Information
- Copyright
- Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.